InMed Pharmaceuticals (INM) Fundamentals 2026 — Revenue Analysis | SniperIQ
InMed Pharmaceuticals (INM) is a CA-listed Healthcare company in Biotechnology with a market capitalization of
InMed Pharmaceuticals (INM) has a market capitalization of approximately
InMed Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
InMed Pharmaceuticals runs a net profit margin of -246.4%, a gross margin of 30.4%, and an operating margin of -246.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
InMed Pharmaceuticals reported revenue of $5M for fiscal year 2025, with net income of -$8M and earnings per share (EPS) of -8.36. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
InMed Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
InMed Pharmaceuticals carries a debt-to-equity ratio of 0.06x and a current ratio of 3.11x, with a market beta of 0.95. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For InMed Pharmaceuticals (INM) the key facts are: market cap
Get InMed Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.